Ubiquitin D Polyclonal Antibody, Cy5 Conjugated

Applications

  • WB

Reactivity

  • Mouse
  • Rat

Predicted Reactivity

  • Human
  • Dog
  • Cow
  • Sheep
  • Pig
  • Horse
  • Rabbit
Overview
Catalog # bs-13006R-Cy5
Product Name Ubiquitin D Polyclonal Antibody, Cy5 Conjugated
Applications WB
Reactivity Mouse, Rat
Predicted Reactivity Human, Dog, Cow, Sheep, Pig, Horse, Rabbit
Specifications
Conjugation Cy5
Host Rabbit
Source KLH conjugated synthetic peptide derived from human Ubiquitin D
Immunogen Range 55-165/165
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 10537
Swiss Prot O15205
Subcellular location Cytoplasm, Nucleus
Synonyms FAT10; UBD-3; GABBR1; Ubiquitin D; Diubiquitin; Ubiquitin-like protein FAT10; UBD
Background Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1L-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses. Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN).
Application Dilution
WB 1:300-5000